LMR Partners’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

LMR Partners’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-782	Closed	-$45K	–	1001
2021 Q2	$45K	Buy	+782	New	+$41.8K	﹤0.01%	1004

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LMR Partners's BCLI Position: Q3 2021 in Review

LMR Partners sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2021, closing a stake of 782 shares — an estimated $45K sold.

LMR Partners first reported a position in BCLI in Q2 2021 and held it in 1 quarter. The position peaked at $45K in Q2 2021. 52 funds tracked by Wall St. Rank hold BCLI as of Q3 2021.

LMR Partners reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 782 BRAINSTORM CELL THERAPUTC shares in Q3 2021, an estimated $45K.
LMR Partners first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2021 and held it in 1 quarter.
LMR Partners's BRAINSTORM CELL THERAPUTC position peaked at $45K in Q2 2021.
52 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.